Real-world data reveal coronavirus jab effectiveness for young people

20 October 2021
comirnaty_vaccine_covid_pfizer_big

Results from a Centers for Disease Control and Prevention (CDC)  trial of Comirnaty, the coronavirus vaccine developed by Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), show a high level of effectiveness at preventing hospitalizations among adolescents.

Among hospitalized COVID-19 patients in the USA aged 12–18 years, 97% had not been vaccinated, the study found.

The findings are consistent with efficacy data from the Pfizer-BioNTech clinical trial program in this age group, which found vaccine efficacy of 100%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology